PolyPid Ltd. cotiza a 5.02 USD y tiene una capitalización bursátil de $102M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial fo…
| Periodo | 2026-08 | 2026-05 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.35 | $-0.35 | $-0.41 | $-0.37 |
| Estimado | $-0.38 | $-0.43 | $-0.33 | $-0.52 |
| Sorpresa | +7.9% | +18.6% | -24.2% | +28.8% |
| Métrica | PYPD | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -311.4% | -40.4% | -271.0% |
| ROA | -153.2% | -32.0% | -121.2% |
| Current Ratio | 1.97 | 2.84 | -0.87 |
| Debt / Equity | — | 0.28 | — |